Also, a Combined Positive Score (CPS) for PD-L1 expression has been shown to be predictive of benefit in recent studies in HNSCC.7 In other tumour types (e.g. non-small cell lung cancer and urothelial carcinoma), immunotherapy is approved only for patients with PD-L1 positive tumours. This evidence concerns the gene CD274 and neoplasm.